Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus weekly oxaliplatin/5‑FU/folinic acid (AIO-FUFOX) in advanced gastro-oesophageal adenocarcinoma
2004-004024-12Phase 2Completed
- Sponsor
- Technical University of Munich
- Start
- Feb 2005
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, oxaliplatin, fluorouracil and folinic acid in gastroesophageal junction adenocarcinoma, gastric adenocarcinoma and esophageal adenocarcinoma (EAC), sponsored by Technical University of Munich. Primary endpoint: Objective response rate by RECIST. Started Feb 2005; status: completed.
02
Drugs
cetuximaboxaliplatinfluorouracilfolinic acid
03
Conditions
gastroesophageal junction adenocarcinomagastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2004-004024-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004024-12.